Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Hemasphere
; 7(8): e907, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-37449196
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Hemasphere
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania